Abstract
Heterozygous familial hypercholesterolemia (FH) is a genetic disorder characterized by high low-density lipoprotein cholesterol levels from birth, which exposes the arteries to high levels of atherogenic lipoproteins lifelong and results in a significantly increased risk of premature cardiovascular events. The diagnosis of FH, followed by an appropriate and early treatment is critical to reduce the cardiovascular burden in this population. Phase I-III clinical trials showed the benefit of proprotein convertase subtilisin kexin 9 inhibitors, both alirocumab and evolocumab, in these patients with an average low-density lipoprotein cholesterol reduction ranging from −40% to −60%. The aim of this review is to address the unmet needs in cholesterol management, elucidate the biology and the clinical benefit of proprotein convertase subtilisin kexin 9 inhibition and finally discuss the open gaps and future directions in the treatment of patients with heterozygous FH.
| Original language | English |
|---|---|
| Pages (from-to) | 343-351 |
| Number of pages | 9 |
| Journal | Vascular Health and Risk Management |
| Volume | 13 |
| DOIs | |
| Publication status | Published - Sep 4 2017 |
| Externally published | Yes |
Fingerprint
Keywords
- Alirocumab
- Cholesterol
- Dyslipidemia
- Evolocumab
- HeFH
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Hematology
- Public Health, Environmental and Occupational Health
- Cardiology and Cardiovascular Medicine
- Pharmacology (medical)
Cite this
Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia : Patient selection and perspectives. / Catapano, Alberico Luigi; Pirillo, Angela; Norata, Giuseppe Danilo.
In: Vascular Health and Risk Management, Vol. 13, 04.09.2017, p. 343-351.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia
T2 - Patient selection and perspectives
AU - Catapano, Alberico Luigi
AU - Pirillo, Angela
AU - Norata, Giuseppe Danilo
PY - 2017/9/4
Y1 - 2017/9/4
N2 - Heterozygous familial hypercholesterolemia (FH) is a genetic disorder characterized by high low-density lipoprotein cholesterol levels from birth, which exposes the arteries to high levels of atherogenic lipoproteins lifelong and results in a significantly increased risk of premature cardiovascular events. The diagnosis of FH, followed by an appropriate and early treatment is critical to reduce the cardiovascular burden in this population. Phase I-III clinical trials showed the benefit of proprotein convertase subtilisin kexin 9 inhibitors, both alirocumab and evolocumab, in these patients with an average low-density lipoprotein cholesterol reduction ranging from −40% to −60%. The aim of this review is to address the unmet needs in cholesterol management, elucidate the biology and the clinical benefit of proprotein convertase subtilisin kexin 9 inhibition and finally discuss the open gaps and future directions in the treatment of patients with heterozygous FH.
AB - Heterozygous familial hypercholesterolemia (FH) is a genetic disorder characterized by high low-density lipoprotein cholesterol levels from birth, which exposes the arteries to high levels of atherogenic lipoproteins lifelong and results in a significantly increased risk of premature cardiovascular events. The diagnosis of FH, followed by an appropriate and early treatment is critical to reduce the cardiovascular burden in this population. Phase I-III clinical trials showed the benefit of proprotein convertase subtilisin kexin 9 inhibitors, both alirocumab and evolocumab, in these patients with an average low-density lipoprotein cholesterol reduction ranging from −40% to −60%. The aim of this review is to address the unmet needs in cholesterol management, elucidate the biology and the clinical benefit of proprotein convertase subtilisin kexin 9 inhibition and finally discuss the open gaps and future directions in the treatment of patients with heterozygous FH.
KW - Alirocumab
KW - Cholesterol
KW - Dyslipidemia
KW - Evolocumab
KW - HeFH
UR - http://www.scopus.com/inward/record.url?scp=85029184357&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029184357&partnerID=8YFLogxK
U2 - 10.2147/VHRM.S130338
DO - 10.2147/VHRM.S130338
M3 - Review article
C2 - 28919772
AN - SCOPUS:85029184357
VL - 13
SP - 343
EP - 351
JO - Vascular Health and Risk Management
JF - Vascular Health and Risk Management
SN - 1176-6344
ER -